The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just noticed over on the NASDAQ website (https://www.nasdaq.com/market-activity/stocks/mxct/short-interest) that, as at, 31 January ~3.15% of the issued shares are currently being shorted. Would love to know who's lending them shares. Wouldn't be surprised if it turned out to be my execution only broker (although I can't find anything in the terms and conditions of either of my brokers to suggest that I have given them permission to lend my shares on their account); wouldn't that be just typical ;-)
If you look at the stock prices of most US biotech companies they have had a really terrible 12 months. I think Maxcyte is just following that. Not sure if it is because there are doubts over the viability or commercialisation of the technology or just that the price of these companies got way out of kilter with future prospects.
Have followed MXCT for some time and SP looks attractive when considering the large fund raise in 2021 and large cash holding. I didn't understand why they needed to raise so much but investors must see medium - long term value. SP has dropped by over 60% from last year's high. Bought 2000 at 442p to dip toe into the water.
We are hosting a webinar with MaxCyte (MXCT) 08 February 2022, which may be of interest to current shareholders or potential investors. Doug Doerfler (President and CEO) will be presenting. You can register here: https://www.sharesoc.org/events/sharesoc-webinar-with-maxcyte-mxct8-february-2022/
With cash of circa $280m+ and an annual cash burn rate of between $15m and $20m it ain't going to disappear any time soon.
Maxcyte is like Abzena. I remember Abzena also had a high cash burn rate, was loss making and had lots of licences for royalties on the drugs that got to market by their customers. The market cap was continously eaten away untill it was bought out for a fraction of its value.
I think this could happen here.
But do you really understand or do you understand the story?
I understand what it does that's why I'm invested and I'll be topping up at levels as this share price pulls back...thing is with this one it's quite difficult to time an entry as this can turn and never see these levels again at any point in the given months so I've been scaling in and will scale in again at 400 then 200 is it gets there. Long term this is a money printing machine with multiple streams and partners. If you don't understand this company it's up to yourself to do some research and wrap your head around what they do...if you do this then I suspect you too will also be invested.. This is one for those happy to play the long game...10 year hold. Not for penny flippers or day trippers. It's a company with a bright future for the future.
Honestly not got the foggiest what this company does. I have tried, I just don't get it. Something to do with putting medicines in cells? Maybe its the future and a great investment but I will stick to the Buffett principle of only invest in something you understand. How many people out there actually understand what this company does?
I hate to be one to blame MMs as a lot of the times it is just shareholders finding something to blame .... but there are such little trades on here. The drop in price can only be explained by a bit of MM bringing it down, or there is a background seller wanting to sell off a big load.
A very quiet board here indeed. I'm thinking this company look set to have a bright future but things do take time. I'll top up if she keeps dropping, next accumulation point would be the 400 level. Let's see what the future brings.
From minute 33.30.....https://www.youtube.com/watch?v=vY6KLjNsXfw
Seems to be a sell off of slow moving stock across the pond. Either for projected Black Friday BTC/ETH rocket or for cash in case of a crash. Palantir are down 25% as well. Not many in it for the long game. Both are 10 year investments for me, so f*ck it. Only a ripple on the pond.
Good to see ned buying in open mkt - 20,000 at $11.12 / £8.32.
Feel this is good value...
MAXCYTE REVENUE JUMPS MORE THAN 50PC IN THIRD QUARTER (from 11 Nov)
Commercial cell engineering company MaxCyte reported total third quarter revenue of $10.1m in an update on Thursday, representing 50% growth compared to the same period in 2020.
The AIM-traded firm said that, excluding strategic platform license (SPL) programme-related revenue, revenue from cell therapy customers was $6.2million for the three months ended 30 September, which was an increase of 38% year-on-year.
SPL programme-related revenue was $2m, which was the received in any quarter to-date, and compared to $0.3m for the same period in 2020.
Revenue from drug discovery customers was $1.9m in the third quarter, a decrease of 5% compared to the same period in 2020, but up sequentially from the second quarter of 2021.
With the addition of Myeloid Therapeutics, Celularity, Sana Biotechnology and Nkarta signed in the year-to-date, MaxCyte said the total number of SPLs now stood at 15.
"We are pleased to report very strong third quarter results driven by ongoing strength in sales to cell therapy customers and robust SPL programme-related revenue," said president and chief executive officer Doug Doerfler.
"We continue to expand our customer base and increase the number of strategic partnerships, now with 15 SPL agreements in place following the announcement of our agreement with Nkarta in early November.
"The vast majority of our SPL agreements enable MaxCyte to participate in pre-commercial milestones and post-commercial sales-based payments on SPL-related programmes."
Doerfler said the company remained "bullish" around the potential for its SPL partnerships to generate meaningful revenue for the business over the next 12-to-18 months and beyond, as its partners continued to see clinical success.
"We are also making important and strategic investments in our business, expanding our marketing, research and development, and product development capabilities, launching innovative solutions to drive future growth, bolstering our leading internal and field-based cell engineering expertise, expanding our manufacturing capabilities as our customers move closer to commercialization, and adding strong talent across all facets of our business.
"Overall, MaxCyte remains well-positioned to support growing adoption of the 'ExPERT' platform technology for cellular-based research and next-generation therapeutic development."
https://www.lse.co.uk/rns/MXCT/license-with-nkarta-inc-viuvv98c4zb1kgp.html
https://healthandwealth.substack.com/p/maxcyte-electroporation
It is very sneaky posting this RNS after hours today. Makes them look like they don't care about investors. Should be reported!
Get a life cm45
Followed by 2 x £110k sales. Coincidence?
https://www.investorschronicle.co.uk/ideas/2021/09/02/shares-i-love-maxcyte/
Appears that the spread tightens once US opens.
Similar to Renx and HCM
Zoom out - SP increased by over 15% in one month. Nothing has changed - excellent mid/long term hold. I continue to hold and anticipate the fluctuations in SP as with most stocks.
Why the desperate selling?
Ask has fallen c7% in 2 hrs+
Nothing has changed for the co. and Nasdaq has yet to open (futures pointing 0.11% + at time of writing)
If Nasdaq are showing $16.50 and the GNP is 1.39 then AIM should be £11.8 or so but it’s about £11. So buy in FTSE and sell on Nasdaq?